Circulating tumor cells as a biomarker for monitoring: Disease progression, treatment response, and minimal residual disease.

被引：0
|
作者：
Raut, Nirmal Vivek
Bharde, Atul
Gourishankar, Aland
Jayant, Sreeja
Garbhe, Meghana
Gosavi, Sayali
Janorkar, Apoorva
D'Souza, Alain
Vasudevan, Aravindan
Khandare, Jayant
机构：
[1] Dr Vishwanath Karad World Peace Univ, Sch Consciousness, Pune, India
[2] Savitribai Phule Pune Univ, Pune, India
[3] Actorius Innovat & Res Pvt Ltd, Pune, India
[4] Actorius Res & Innovat, Pune, India
[5] Actorius Res & Innovat Co, Cupertino, CA USA
[6] Onecell Diag, Cupertino, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15021
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Liquid Biopsies for Monitoring Medulloblastoma: Circulating Tumor DNA as a Biomarker for Disease Progression and Treatment Response
    Buccilli, Barbara
    Molina, Maria A. Rodriguez
    Palomeque, Daniela P. Redrovan
    Saban, Cindy A. Herrera
    Caliwag, Fides M. C.
    Flores, Cristian Jenifer S. Contreras
    Abeysiriwardana, Chamathi W. J.
    Diarte, Edna
    Arruarana, Victor S.
    Martinez, Ernesto Calderon
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (01)
  • [2] Minimal residual disease and circulating tumor cells in breast cancer
    Ignatiadis, Michail
    Reinholz, Monica
    BREAST CANCER RESEARCH, 2011, 13 (05)
  • [3] Minimal residual disease and circulating tumor cells in breast cancer
    Michail Ignatiadis
    Monica Reinholz
    Breast Cancer Research, 13
  • [4] Utility of circulating tumor DNA in esophageal cancer: A potential prognostic biomarker in tumor staging, monitoring of treatment response and detection of recurrent disease.
    Cabalag, Carlos Suhady
    Yates, Michael
    Corrales, Mariana B.
    Yeh, Paul
    Wong, Stephen Q.
    Zhang, Bonnie
    Fujihara, Kenji M.
    Chong, Lynn
    Hii, Michael
    Dawson, Sarah-Jane
    Phillips, Wayne A.
    Duong, Cuong P.
    Clemons, Nicholas J.
    CANCER RESEARCH, 2021, 81 (13)
  • [5] Circulating Tumor DNA as a Marker of Minimal Residual Disease
    Fangman, Ben
    Raghav, Kanwal
    Kopetz, Scott
    ONCOLOGY-NEW YORK, 2022, 36 (10): : 600 - 603
  • [6] MINIMAL RESIDUAL DISEASE AS A BIOMARKER
    Buccisano, F.
    Maurillo, L.
    Del Principe, M. I.
    Di Veroli, A.
    Amadori, S.
    Voso, M. T.
    Lo-Coco, F.
    Arcese, W.
    Venditti, A.
    HAEMATOLOGICA, 2017, 102 : 180 - 182
  • [7] Circulating tumor cells are correlated with disease progression and treatment response in an orthotopic hepatocellular carcinoma model
    Yan, Jun
    Fan, Zhichao
    Wu, Xiufeng
    Xu, Min
    Jiang, Jiahao
    Tan, Changjun
    Wu, Weizhong
    Wei, Xunbin
    Zhou, Jian
    CYTOMETRY PART A, 2015, 87A (11) : 1020 - 1028
  • [8] Non-Invasive Monitoring of Urinary KRAS Circulating Tumor DNA for Treatment Response and Minimal Residual Disease in Patients with Lung Adenocarcinoma.
    Randall, James Michael
    Erlander, Mark G.
    Vibat, Cecile Rose T.
    Hancock, Saege
    Melnikova, Vlada
    Cohen, Ezra E. W.
    Lippman, Scott Michael
    Kurzrock, Razelle
    Husain, Hatim
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] Circulating tumor DNA (ctDNA) to evaluate minimal residual disease (MRD), treatment response, and posttreatment prognosis in pancreatic adenocarcinoma
    Ueberroth, Benjamin E.
    Jones, Jeremy C.
    Bekaii-Saab, Tanios S.
    PANCREATOLOGY, 2022, 22 (06) : 741 - 748
  • [10] Clinical significance of circulating tumor cells in colorectal cancer with peritoneal metastases: a prospective cohort study using a novel method for monitoring treatment response, and assessing minimal residual disease
    Fruhling, Petter
    Moberg, Louice
    Ghanipour, Lana
    Birgisson, Helgi
    Graf, Wilhelm
    Ericsson, Christer
    Cashin, P. H.
    INTERNATIONAL JOURNAL OF SURGERY, 2024, 110 (11) : 7187 - 7195
12345